Publication

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J. & van Geffen, W. H., 12-Aug-2019, In : Cochrane Database of Systematic Reviews. 2019, 8, 14 p., CD013382.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Best first‐line therapy for patients with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

    Final publisher's version, 496 KB, PDF document

DOI

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

Original languageEnglish
Article numberCD013382
Number of pages14
JournalCochrane Database of Systematic Reviews
Volume2019
Issue number8
Publication statusPublished - 12-Aug-2019

ID: 112043908